These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

141 related items for PubMed ID: 15013590

  • 21. Second-line chemotherapy with weekly cisplatin and irinotecan in patients with refractory lung cancer.
    Nakanishi Y, Takayama K, Takano K, Inoue K, Osaki S, Wataya H, Takaki Y, Minami T, Kawasaki M, Hara N.
    Am J Clin Oncol; 1999 Aug; 22(4):399-402. PubMed ID: 10440199
    [Abstract] [Full Text] [Related]

  • 22. European organization for research and treatment of cancer (EORTC) 08957 phase II study of topotecan in combination with cisplatin as second-line treatment of refractory and sensitive small cell lung cancer.
    Ardizzoni A, Manegold C, Debruyne C, Gaafar R, Buchholz E, Smit EF, Lianes P, ten Velde G, Bosquee L, Legrand C, Neumaier C, King K, Giuseppe giaccone European organization for research and treatment of cancer (EORTC) lung cancer group.
    Clin Cancer Res; 2003 Jan; 9(1):143-50. PubMed ID: 12538462
    [Abstract] [Full Text] [Related]

  • 23. A phase II study of biweekly irinotecan and cisplatin for patients with extensive stage disease small cell lung cancer.
    Bae SH, Ryoo HM, Do YR, Song HS, Kwon KY, Kim MK, Lee KH, Hyun MS, Lee WS, Hur IK, Baek JH, Park KU.
    Lung Cancer; 2008 Jan; 59(1):76-80. PubMed ID: 17767977
    [Abstract] [Full Text] [Related]

  • 24. Irinotecan (CPT-11) in combination with weekly administration of cisplatin (CDDP) for non-small-cell lung cancer.
    Kobayashi K, Shinbara A, Kamimura M, Takeda Y, Kudo K, Kabe J, Hibino S, Hino M, Shibuya M, Kudoh S.
    Cancer Chemother Pharmacol; 1998 Jan; 42(1):53-8. PubMed ID: 9619758
    [Abstract] [Full Text] [Related]

  • 25. Phase II study of irinotecan plus cisplatin in patients with advanced non-small-cell lung cancer.
    DeVore RF, Johnson DH, Crawford J, Garst J, Dimery IW, Eckardt J, Eckhardt SG, Elfring GL, Schaaf LJ, Hanover CK, Miller LL.
    J Clin Oncol; 1999 Sep; 17(9):2710-20. PubMed ID: 10561345
    [Abstract] [Full Text] [Related]

  • 26.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 27.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 28.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 29. CPT-11: a new derivative of camptothecin for the treatment of refractory or relapsed small-cell lung cancer.
    Masuda N, Fukuoka M, Kusunoki Y, Matsui K, Takifuji N, Kudoh S, Negoro S, Nishioka M, Nakagawa K, Takada M.
    J Clin Oncol; 1992 Aug; 10(8):1225-9. PubMed ID: 1321891
    [Abstract] [Full Text] [Related]

  • 30. [A case-control study of prevention of irinotecan-induced diarrhea: the reducing side effects of irinotecan by oral alkalization combined with control of defecation].
    Takeda Y, Kobayashi K, Akiyama Y, Soma T, Handa S, Kudoh S, Kudo K.
    Gan To Kagaku Ryoho; 2002 Jul; 29(7):1171-7. PubMed ID: 12145998
    [Abstract] [Full Text] [Related]

  • 31.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 32.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 33. Phase II study of irinotecan and carboplatin in patients with the refractory or relapsed small cell lung cancer.
    Hirose T, Horichi N, Ohmori T, Ogura K, Hosaka T, Ando K, Ishida H, Noguchi H, Adachi M.
    Lung Cancer; 2003 Jun; 40(3):333-8. PubMed ID: 12781433
    [Abstract] [Full Text] [Related]

  • 34. Three-week schedule of irinotecan plus cisplatin in patients with previously untreated extensive-stage small-cell lung cancer.
    Hong YS, Lee HR, Park S, Lee SC, Hwang IG, Park BB, Lee J, Ahn JS, Ahn MJ, Lim HY, Park K.
    Br J Cancer; 2006 Dec 18; 95(12):1648-52. PubMed ID: 17133266
    [Abstract] [Full Text] [Related]

  • 35.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 36.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 37.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 38.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 39.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 40.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 8.